31 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
AND THEIR CRITICAL ROLE IN INFLAMMATION Recruit other immune cells Defend against pathogens Cleanup senescent or dead cells Control tissue homeostasis
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
8:00am
is currently enrolling patients at clinical trial sites in Israel and was recently cleared to expand into Spain, is expected to recruit up to 152
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
, is expected to recruit up to 152 severe or critical COVID-19 patients. It is designed to assess the safety and efficacy of AllocetraTM when administered
6-K
EX-99.1
fmhy2i2myntwyw6mci35
10 Nov 21
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
8:00am
6-K
EX-99.1
2bqe5h35
22 Sep 21
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
96z67l ss6
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
pfjohagq82zwitgl
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
424B5
4fz b85lb2z0sgd2afj9
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
yuxr7ozkyj26w sz
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
842pp4
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
qa7m4nfed8pktys
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
dfxc1h8fhseupay
3 Nov 20
Current report (foreign)
9:14am
6-K
EX-99.1
lpmw 9mu4
27 Oct 20
Report of Foreign Private Issuer
8:03am
6-K
EX-99.1
on7j mhg4
22 Oct 20
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:49am
424B5
b0hek5gqa e5mdyh
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
EX-99.1
9qcuqdcyn18fwiw4q
13 Oct 20
Report of Foreign Private Issuer
9:30am
6-K
EX-99.1
lkd9w6cunksllt
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am